Building a CAR-T Toolbox for More Comprehensive Assessment of Cell Therapies
Scientists developing chimeric antigen receptor (CAR) T cell products strive to maximize specificity, potency, and persistence of these therapies, but the inability to predict treatment efficacy and response remains a significant challenge. Daniel Hui, PhD, Associate Director of Analytical Development at Tmunity Therapeutics, addresses these challenges and highlights the company’s multiplatform approach to build an innovative “toolbox” of orthogonal assays to provide a comprehensive set of...
Source: genengnews.com